Compare Duolingo Inc (DUOL) vs Summit Therapeutics Inc (SMMT) Price & Performance

Duolingo (DUOL) trades at $151.16, down 0.37% on the day, as the stock consolidates near recent highs. The company demonstrates strong fundamental momentum with Q2 2026 EPS of $0.66 beating expectations of $0.604, marking the third consecutive quarterly beat. Revenue growth remains robust at 29% year-over-year, supported by a 36% net income margin. Technical indicators show a bullish trend with the stock trading above key support levels, though RSI suggests potential near-term overbought conditions.

Duolingo's outlook remains positive with accelerating revenue growth and expanding profitability, though the stock trades at a premium valuation with a P/E of 17.87. Key risks include CEO share sales and competitive pressures in the edtech space. Analyst consensus leans cautious with 37.5% buy ratings versus 54.2% hold, suggesting potential for re-rating if growth momentum continues.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.